Lunai Bioworks (NASDAQ:LNAI) Issues Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) issued its quarterly earnings results on Friday. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.02 million for the quarter.

Lunai Bioworks Price Performance

Shares of LNAI opened at $0.26 on Friday. The firm has a 50-day moving average of $0.34 and a 200-day moving average of $0.72. Lunai Bioworks has a one year low of $0.15 and a one year high of $4.50. The company has a market cap of $6.22 million, a PE ratio of 5.14 and a beta of 0.34.

Analysts Set New Price Targets

Several brokerages have issued reports on LNAI. Wall Street Zen lowered shares of Lunai Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Friday, April 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC acquired a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks at the end of the most recent reporting period. 71.41% of the stock is currently owned by hedge funds and other institutional investors.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.